| |
| |
|
| Insider
Information: |
Cagnoni Pablo J |
| Relationship: |
President, R&D |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
293,350 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$10,731,557 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
293,350 |
|
|
| Total
Value |
$10,731,557 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
3
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
-3.0
|
| Percentage
Gain/Loss : |
 74.7%
|
 -281.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Allos Therapeutics Inc |
ALTH |
Sr. VP, Chief Medical ... |
2009-09-30 |
25,200 |
2003-06-30 |
0 |
Premium* |
|
|
Onyx Pharmaceuticals Inc |
ONXX |
EVP, Global R&D and Te... |
2013-10-01 |
0 |
2013-03-11 |
0 |
Premium* |
|
|
Crispr Therapeutics Ag |
CRSP |
Director |
2019-11-12 |
0 |
2018-07-03 |
0 |
Premium* |
|
|
Rubius Therapeutics, Inc. |
RUBY |
Director |
2023-02-01 |
66,082 |
2020-04-14 |
0 |
Premium* |
|
|
Incyte Corp |
INCY |
President, R&D |
2023-07-14 |
202,068 |
2023-06-05 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| INCY |
Incyte Corp |
President, R&D |
• – – |
2023-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
9,668 |
202,068 |
0 |
- |
|
| INCY |
Incyte Corp |
President, R&D |
• – – |
2023-06-05 |
4/A |
A |
$0.00 |
$0 |
D/D |
192,400 |
192,400 |
0 |
- |
|
| INCY |
Incyte Corp |
President, R&D |
• – – |
2023-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
179,613 |
179,613 |
0 |
- |
|
| RUBY |
Rubius Therapeutics, Inc. |
Director |
– • – |
2023-02-01 |
4 |
S |
$0.25 |
$2,112 |
D/D |
(8,448) |
66,082 |
0 |
% |
|
| RUBY |
Rubius Therapeutics, Inc. |
Director |
– • – |
2023-01-31 |
4 |
S |
$0.24 |
$1,745 |
D/D |
(7,240) |
74,530 |
0 |
% |
|
| RUBY |
Rubius Therapeutics, Inc. |
Director |
– • – |
2023-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
81,770 |
0 |
- |
|
| RUBY |
Rubius Therapeutics, Inc. |
Director |
– • – |
2023-01-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,250 |
56,770 |
0 |
- |
|
| RUBY |
Rubius Therapeutics, Inc. |
CEO and President |
• • – |
2022-02-01 |
4 |
S |
$6.57 |
$44,236 |
D/D |
(6,730) |
35,520 |
0 |
% |
|
| RUBY |
Rubius Therapeutics, Inc. |
CEO and President |
• • – |
2022-01-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,250 |
42,250 |
0 |
- |
|
| RUBY |
Rubius Therapeutics, Inc. |
CEO and President |
• • – |
2020-04-14 |
4 |
B |
$4.70 |
$98,694 |
D/D |
21,000 |
21,000 |
2.81 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2019-11-12 |
4 |
AS |
$55.00 |
$412,500 |
D/D |
(7,500) |
0 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2019-11-12 |
4 |
OE |
$5.59 |
$41,925 |
D/D |
7,500 |
7,500 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2019-10-30 |
4 |
AS |
$52.00 |
$390,000 |
D/D |
(7,500) |
0 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2019-10-30 |
4 |
OE |
$5.59 |
$41,925 |
D/D |
7,500 |
7,500 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-07-05 |
4 |
AS |
$62.00 |
$104,408 |
D/D |
(1,684) |
0 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-07-05 |
4 |
OE |
$5.59 |
$9,414 |
D/D |
1,684 |
1,684 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-07-03 |
4 |
AS |
$62.00 |
$360,592 |
D/D |
(5,816) |
0 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-07-03 |
4 |
OE |
$5.59 |
$32,511 |
D/D |
5,816 |
5,816 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Global R&D and Tech Ops |
• – – |
2013-10-01 |
4 |
D |
$125.00 |
$2,032,125 |
D/D |
(16,257) |
0 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Global R&D and Tech Ops |
• – – |
2013-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
16,257 |
16,257 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Sr. VP, Chief Medical Officer |
• – – |
2009-09-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(61,373) |
25,200 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Sr. VP, Chief Medical Officer |
• – – |
2009-03-20 |
4 |
AS |
$6.63 |
$41,079 |
D/D |
(6,200) |
86,573 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Sr. VP, Chief Medical Officer |
• – – |
2009-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
23,873 |
92,773 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Sr. VP, Chief Medical Officer |
• – – |
2008-03-20 |
4 |
AS |
$5.28 |
$32,270 |
D/D |
(6,100) |
68,900 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Sr. VP, Chief Medical Officer |
• – – |
2007-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
75,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
